NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• NRx Pharmaceuticals has received a consensus rating of "Moderate Buy" from seven analysts, with four buy ratings and one strong buy rating, while the average price target is $34.50.
• Anson Funds Management LP increased its stake in NRx Pharmaceuticals by 535.1%, owning approximately 6.82% of the company, demonstrating strong institutional interest.
• The company's stock opened at $3.18, with a twelve-month low of $1.12 and a high of $6.01, reflecting volatility in its market performance.

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $34.50.

Several equities research analysts have recently commented on NRXP shares. Zacks Research raised NRx Pharmaceuticals to a "hold" rating in a report on Wednesday, September 10th. D. Boral Capital reissued a "buy" rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Thursday, September 25th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of NRx Pharmaceuticals in a report on Thursday. BTIG Research reissued a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th.

Institutional Investors Weigh In On NRx Pharmaceuticals

A hedge fund recently raised its stake in NRx Pharmaceuticals stock. Anson Funds Management LP increased its stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 535.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,179,061 shares of the company's stock after buying an additional 993,401 shares during the quarter. Anson Funds Management LP owned approximately 6.82% of NRx Pharmaceuticals worth $2,417,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.27% of the company's stock.

NRx Pharmaceuticals Stock Up 4.6%

NASDAQ:NRXP opened at $3.18 on Friday. NRx Pharmaceuticals has a twelve month low of $1.12 and a twelve month high of $6.01. The business has a 50 day moving average price of $2.90 and a two-hundred day moving average price of $2.74. The company has a market cap of $63.00 million, a P/E ratio of -1.42 and a beta of 1.74.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.